Limits...
Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Clafshenkel WP, King TL, Kotlarczyk MP, Cline JM, Foster WG, Davis VL, Witt-Enderby PA - Evid Based Complement Alternat Med (2012)

Bottom Line: Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits.However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice.A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

ABSTRACT
Morinda citrifolia (noni) is reported to have many beneficial properties, including on immune, inflammatory, quality of life, and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the effects of Tahitian Noni Juice (TNJ) on mammary carcinogenesis were examined in MMTV-neu transgenic mice. Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits. However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form of cancer occurred with the mouse equivalent of a recommended dose for humans (<3 oz/day). A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modified reproductive responses are needed to characterize its potential as a CAM therapy for women with and without HER2(+) breast cancer.

No MeSH data available.


Related in: MedlinePlus

Chronic administration of 10% TNJ does not elevate serum levels of markers for hepatic renal toxicity in 14-month-old female MMTV-neu mice. (a) Serum alanine aminotransferase (ALT), a hepatic serum marker, in control, n = 7, and 10% TNJ-treated, n = 7, mice. (b) Serum aspartate aminotransferase (AST), a marker of liver damage, in control, n = 6, and 10% TNJ, n = 6, groups. (c) Serum blood nitrogen urea (BUN), a renal function marker, in control, n = 6, and 10% TNJ, n = 2, groups. Only animals necropsied within 48 hours of the assay were used to analyze BUN levels. No significance was detected for any of the markers, P > 0.05; P values determined by Student's t-test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3351229&req=5

fig5: Chronic administration of 10% TNJ does not elevate serum levels of markers for hepatic renal toxicity in 14-month-old female MMTV-neu mice. (a) Serum alanine aminotransferase (ALT), a hepatic serum marker, in control, n = 7, and 10% TNJ-treated, n = 7, mice. (b) Serum aspartate aminotransferase (AST), a marker of liver damage, in control, n = 6, and 10% TNJ, n = 6, groups. (c) Serum blood nitrogen urea (BUN), a renal function marker, in control, n = 6, and 10% TNJ, n = 2, groups. Only animals necropsied within 48 hours of the assay were used to analyze BUN levels. No significance was detected for any of the markers, P > 0.05; P values determined by Student's t-test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice.

Mentions: The possibility of TNJ-induced toxicity was assessed in aged mice consuming the equivalent of a recommended dose in women for most of their adult life. Serum levels of the hepatic enzymes, aspartate transferase (AST) and alanine transferase (ALT), were examined in the TNJ-treated mice, since these are considered markers of liver damage in humans and both were elevated in the case reports on hepatotoxicity with noni use [19–22, 36, 37]. In addition, serum blood urea nitrogen (BUN), a marker of renal function, was assessed. None of these three markers were abnormally elevated or disproportionate to levels in the control group (Figure 5). These results were supported by the absence of toxin-induced damage to tissue ultrastructure in sections of liver and kidney from the 10% TNJ-treated group (data not shown). Thus, long-term administration of TNJ in the MMTV-neu model did not have any detectable adverse effects on the liver and kidney tissues or markers assessed in this study.


Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Clafshenkel WP, King TL, Kotlarczyk MP, Cline JM, Foster WG, Davis VL, Witt-Enderby PA - Evid Based Complement Alternat Med (2012)

Chronic administration of 10% TNJ does not elevate serum levels of markers for hepatic renal toxicity in 14-month-old female MMTV-neu mice. (a) Serum alanine aminotransferase (ALT), a hepatic serum marker, in control, n = 7, and 10% TNJ-treated, n = 7, mice. (b) Serum aspartate aminotransferase (AST), a marker of liver damage, in control, n = 6, and 10% TNJ, n = 6, groups. (c) Serum blood nitrogen urea (BUN), a renal function marker, in control, n = 6, and 10% TNJ, n = 2, groups. Only animals necropsied within 48 hours of the assay were used to analyze BUN levels. No significance was detected for any of the markers, P > 0.05; P values determined by Student's t-test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3351229&req=5

fig5: Chronic administration of 10% TNJ does not elevate serum levels of markers for hepatic renal toxicity in 14-month-old female MMTV-neu mice. (a) Serum alanine aminotransferase (ALT), a hepatic serum marker, in control, n = 7, and 10% TNJ-treated, n = 7, mice. (b) Serum aspartate aminotransferase (AST), a marker of liver damage, in control, n = 6, and 10% TNJ, n = 6, groups. (c) Serum blood nitrogen urea (BUN), a renal function marker, in control, n = 6, and 10% TNJ, n = 2, groups. Only animals necropsied within 48 hours of the assay were used to analyze BUN levels. No significance was detected for any of the markers, P > 0.05; P values determined by Student's t-test. Mean ± SEM are shown; TNJ: Tahitian Noni Juice.
Mentions: The possibility of TNJ-induced toxicity was assessed in aged mice consuming the equivalent of a recommended dose in women for most of their adult life. Serum levels of the hepatic enzymes, aspartate transferase (AST) and alanine transferase (ALT), were examined in the TNJ-treated mice, since these are considered markers of liver damage in humans and both were elevated in the case reports on hepatotoxicity with noni use [19–22, 36, 37]. In addition, serum blood urea nitrogen (BUN), a marker of renal function, was assessed. None of these three markers were abnormally elevated or disproportionate to levels in the control group (Figure 5). These results were supported by the absence of toxin-induced damage to tissue ultrastructure in sections of liver and kidney from the 10% TNJ-treated group (data not shown). Thus, long-term administration of TNJ in the MMTV-neu model did not have any detectable adverse effects on the liver and kidney tissues or markers assessed in this study.

Bottom Line: Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits.However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice.A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling.

View Article: PubMed Central - PubMed

Affiliation: Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282, USA.

ABSTRACT
Morinda citrifolia (noni) is reported to have many beneficial properties, including on immune, inflammatory, quality of life, and cancer endpoints, but little is known about its ability to prevent or treat breast cancer. To test its anticancer potential, the effects of Tahitian Noni Juice (TNJ) on mammary carcinogenesis were examined in MMTV-neu transgenic mice. Mammary tumor latency, incidence, multiplicity, and metastatic incidence were unaffected by TNJ treatment, which suggests that it would not increase or decrease breast cancer risk in women taking TNJ for its other benefits. However, noni may be useful to enhance treatment responses in women with existing HER2/neu breast cancer since TNJ resulted in significant reductions in tumor weight and volume and in longer tumor doubling times in mice. Remarkably, its ability to inhibit the growth of this aggressive form of cancer occurred with the mouse equivalent of a recommended dose for humans (<3 oz/day). A 30-day treatment with TNJ also induced significant changes in mammary secondary ductule branching and lobuloalveolar development, serum progesterone levels, and estrous cycling. Additional studies investigating TNJ-induced tumor growth suppression and modified reproductive responses are needed to characterize its potential as a CAM therapy for women with and without HER2(+) breast cancer.

No MeSH data available.


Related in: MedlinePlus